Syros eyes strategic shift after failure of hitherto promising cancer drug
The company plans to discontinue development of its intravenous drug, SY-1365, and refocus on an oral therapy with the same molecular target following the former's failure in Phase I. Shares of Syros fell more than 32 percent on the news.